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Abstract Intragastric balloons are associated with (1) early
period intolerance, (2) diminished effect within 3–4 months,
and (3) bowel obstruction risk mandating removal at
6 months. The introduction of an adjustable balloon could
improve comfort and offer greater efficacy. A migration
prevention function, safely enabling prolonged implanta-
tion, could improve efficacy and weight maintenance post-
extraction. The first implantations of an adjustable balloon
with an attached migration prevention anchor are reported.
The primary endpoint was the absence of bowel perfora-
tion, obstruction, or hemorrhage. Eighteen patients with
mean BMI of 37.3 were implanted with the Spatz
Adjustable Balloon system (ABS) for 12 months. Balloon
volumes were adjusted for intolerance or weight loss
plateau. Mean weight loss at 24 weeks was 15.6 kg with
26.4% EWL (percent of excess weight loss) and 24.4 kg
with 48.8% EWL at 52 weeks. Sixteen adjustments were
successfully performed. Six downward adjustments allevi-
ated intolerance, yielding additional mean weight loss of
4.6 kg. Ten upward adjustments for weight loss plateau
yielded a mean additional weight loss of 7 kg. Seven
balloons were removed prematurely. Complications neces-
sitating early removal included valve malfunction (1),
gastritis (1), Mallory–Weiss tear (1), NSAID (2× dose/
2 weeks) perforating ulcer (1), and balloon deflation (1).
Two incidents of catheter shear from the chain: one passed
uneventfully and one caused an esophageal laceration
without perforation during extraction. The Spatz ABS has
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DOI 10.1007/s11695-011-0424-zbeen successfully implanted in 18 patients. (1) Upward
adjustments yielded additional weight loss. (2) Downward
adjustments alleviated intolerance, with continued weight
loss. (3) Preliminary 1-year implantation results are
encouraging.
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Introduction
There are 300 million obese in the world population, many
of whom are in need of a medical device that will afford
them significantly better results than current weight loss
drugs and commercial weight loss systems. While severe
technical failures led to the removal of weight loss balloons
from the US market in 1985, the next generation intra-
gastric balloons (IGBs) were totally redesigned and have
been successfully used for the last 17 years outside of the
USA. The published results reveal an average weight loss
of 12–15 kg over 6 months [1–16]. Nevertheless, current
generation IGBs have limitations; they have been associat-
ed with (1) deflation and bowel obstruction, (2) loss of
effect after 2 to 3 months, (3) limitation to a 6-month
implantation time, (4) significant nausea, vomiting, and
discomfort in the early implantation period, necessitating
balloon extraction in 4–7% of patients [1, 2], (5) balloon
extraction requiring purchase of a dedicated tool, and (6)
difficulty adjusting volume after implantation—technically,
the Allergan balloon can be adjusted, but it is time
consuming, tedious, impractical, and has essentially not
been done for the last 17 years. The Endogast device is an
air-filled balloon that is adjustable; however, it requires
percutaneous anchoring to the abdominal wall, tunneling of
the inflation tube subcutaneously by a surgeon, and reports
a 12.2% subcutaneous infection rate [17].
The introduction of the Spatz Adjustable Balloon system
(ABS) offers features that address these limitations. The
aim of this first-in-man study is to report early safety and
effectiveness results, and to encourage discussions as to
how to best utilize this new generation IGB for chronic
endoscopic weight loss management.
Patients and Methods
Following Ethics committee approval at the University
Hospital in Ostrava, Czech Republic, a 6-month first-in-
man implantation study was undertaken in accordance with
the ethical standards of the Helsinki Declaration of 1975, as
revised in 2000. Patients were enrolled between October
2009 and March 2010. The primary endpoint was the
absence of bowel obstruction, perforation, or significant
hemorrhage. Additionally, weight loss at 12, 24, and
52 weeks and percent of excess weight loss (% EWL)
were also assessed.
The Spatz ABS (Spatz FGIA, Inc., NY, USA) was used
in 18 patients, who were selected according to criteria used
by currently CE Marked IGBs. Inclusion criteria included
BMI>27 and those individuals in need of preoperative
weight loss. Exclusion criteria were similar to the currently
approved IGBs. Informed consent was obtained from all
patients. Pre-implantation evaluation by a psychologist,
dietician, and an experienced IGB endoscopist identified 18
patients appropriate for implantation. A binge eating scale
was used to identify and exclude potential binge eaters.
During the course of the study, the Ethics Committee
approved extension of the implantation period to
12 months.
The Spatz ABS is composed of a silicone balloon that is
mounted on a catheter on one surface. The catheter exits the
balloon and has two loops that are perpendicular to each
other, the larger of which has a metal chain that allows
straightening of the curve, yet confers non-crushability (see
Fig. 1). This non-collapsible loop maintains its 7-cm
diameter in the gastric lumen and is meant to prevent or
delay a deflated balloon from passing through the pylorus
and duodenum and evade endoscopic extraction. A highly
visible white valve is connected to a stretchable inflation
tube that exits the catheter. The stretchable inflation tube
can be pulled out of the stomach with a snare, enabling
balloon volume adjustability, while the balloon remains in
the stomach. A highly visible blue clasp at the end of the
catheter allows easy extraction with a standard polypec-
tomy snare. Calibrations on the pusher identify device
position during the implantation procedure. The device is
straightened with a guidewire and is inserted similar to the
passage of an oro-gastric tube, with the removal of the
Large Loop with Internal Chain
Blue clasp for retrieval
Small loop of catheter
White Inflation Valve Inflation Tube
Fig. 1 Inflated balloon without stabilizer band (deployed state in gastric
lumen)
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esophageal junction. Generation 1 device was implanted in
the first five patients (Figs. 1 and 2). Generation 2 device
added a stabilizer band which maintained the larger loop in
a closed position (Figs. 3 and 4). Thirteen patients were
implanted with Generation 2 device. Balloons were deflated
via the inflation valve or via needle catheter puncture, at the
investigator’s discretion. Devices were extracted with a
standard polypectomy snare.
Generation 2
Eighteen patients (15 female, three male) with a mean BMI of
37.3 (range 29.4–53.2), a mean weight of 108.8 kg (range
89–163), a mean excess weight of 46.3 kg (range 26.8–73.6),
and a mean age of 39 (range 21–57) were implanted with the
Spatz ABS. Patients were followed up by a dietician and a
gastroenterologist on a regular basis (weeks 1, 6, 12, 18, 24,
30, 36, 42, 52, and 60 with the principal investigator and/or
dietician). The first five patients were implanted with
Generation 1 device. After three of the first five patients had
distal catheter tip migration into the duodenum, a stabilizer
band was created to keep the large loop of the catheter closed.
The next 13 patients were implanted with the Generation 2
device. None had distal catheter tip migration into the
duodenum. One patient had the small loop migrate into the
duodenum on day 14 which was pulled back into the stomach
endoscopically, and has not recurred.
The Spatz ABS was implanted following a standard
endoscopy under the sedation of an anesthesiologist. The
first patient underwent general anesthesia, while the
subsequent patients underwent conscious sedation using a
narcotic, and midazolam, with or without propofol, at the
anesthesiologist’s discretion. The Spatz ABS was initially
inflated with 400 ml of sterile normal saline, with the
exception of three patients that were inflated with 350, 475,
and 500 ml, respectively. The initial protocol called for
externalizing the inflation tube valve by leaving the
extension tube out of the mouth and securing to the side
of the mouth. The idea was to inflate or deflate the balloon
4 h after the procedure according to patient symptoms—
hence, the three different volumes (350, 375, and 500). The
first three patients experienced discomfort when the valve
was lowered back down the throat—the procedure was
discontinued and the protocol was adjusted accordingly.
The first five patients were observed overnight in the
hospital, while the remaining patients were discharged on
the day of the procedure. All patients were treated with
Pantoprazole 40 mg BID for 30 days followed by 40 mg
daily for the remainder of the implantation period. Anti-
emetics and analgesics were prescribed for the first 3 days
post-implantation. All patients were discharged on clear
liquid diet for 3 days, followed by a 1,000-kcal diet.
Results
The primary endpoint was met successfully by not having a
single patient with a bowel obstruction, perforation, or
significant hemorrhage. There were no deaths, and a single
Fig. 4 Insertion assembly with stabilizer band (arrow)
Fig. 3 Balloon with stabilizer band (arrow)
Blue Clasp for retrieval
Straightened Chain within large loop of catheter 
White Valve
Guidewire
Inflation Tube
Calibrations on pushing catheter
Folded Balloon
Fig. 2 Insertion assembly without stabilizer band
OBES SURG (2011) 21:1499–1507 1501SAE (hospitalization) which was determined by the
investigator to be unrelated to the IGB (patient no. 9 took
double dose NSAID × 14 days).
Implantation times varied from 20 to 60 min on the first five
patients due to a floppy guidewire. Subsequent implantation
t i m e si nt h er e m a i n i n g1 3p a t i e n t sr a n g e df r o m8t o1 5m i n .
Weight loss results are displayed in Table 1. Mean
weight loss at 12 weeks was 11.1 kg with a 26% EWL.
Mean weight loss at 24 weeks was 15.7 kg with a 36%
EWL. Mean weight loss at 36 weeks was 20.4 kg with a
40.4% EWL. Mean weight loss at 52 weeks was 24.4 kg
with a 48.8% EWL. Therefore, we also demonstrated that
with the Spatz adjustable balloon, patients safely continue
to lose weight beyond 6 months.
Follow-Up Visit Compliance
Follow-up visits with dietician and behavior modification
experts havebeenshowntocorrelate withsuccessfuloutcome
[15]. We have defined successful outcome to be >25% EWL.
Table 2 shows the direct correlation.
Adjustments
The first adjustment was performed without endoscopic
observation. This led to inflation tube kinking and tube
rupture. The balloon was removed without any adverse
event. The following 16 adjustments were performed
successfully (Table 3). Six patients underwent downward
adjustments with a mean volume of 117 ml. Intolerance
was alleviated, and they continued to lose weight, with a
mean additional weight loss of 4.6 kg after the adjustment.
The other ten patients were adjusted upward for weight loss
plateau, with a mean addition of 188 ml. Their mean
additional weight loss following adjustment was 7 kg.
Comorbidities
Improvements or stability of comorbidities are shown in
Table 4.
Adverse Events
Patients experienced varying degrees of nausea, vomiting, and
abdominal pain after implantation. Our data does not suggest
any correlation between degree of post-implantation symptoms
and successful outcome (defined as >25% EWL). See Table 5.
Symptoms after adjustments were much lighter and
better tolerated. See Table 6.
Seven of the 18 balloons (39%) were removed during
the course of the study, as provided in detail in Table 7.
Patient no. 5 was noted to have moderate erosive
gastritis at initial endoscopy, which, at the time was not
deemed a contraindication to the implantation. Nausea and
pain recurred at 6 weeks after implantation necessitating
device removal. At explantation, the erosive gastritis had
Table 1 Weight loss
Pt Device BMI Wt
(kg)
Excess wt
(kg)
Weight loss (kg)/%
EWL
Weight loss (kg)/%
EWL
Weight loss (kg)/%
EWL
Weight loss (kg)/%
EWL
Week 12 Week 24 Week 36 Week 52
1 Gen 1 39 135 57 11 kg/19.3% 12 kg/21.1% 16 kg/28.1% 20.5 kg/35.1%
2 Gen 1 42 115 53 19 kg/35.8% 28 kg/52.8% 34 kg/64.2% 45 kg/85.4%
4 Gen 1 36 123 50 20 kg/40% 30 kg/60% 35.5 kg/71% 41 kg/82%
8 Gen 2 37 99 37 10 kg/27% 18 kg/48.6% 23.5 kg/63.9% 32 kg/86.5%
9 Gen 2 32 98 30 7 kg/23.3% 9 kg/30%
10 Gen 2 33 89 28 11 kg/39.3% 14 kg/50%
11 Gen 2 41 110 48 10 kg/20.8% 13 kg/27.1% 19 kg/39.8% 29 kg/60.4%
12 Gen 2 33 98 33 5 kg/15.2% 8 kg/24.2% 6 kg/18.3% 3 kg/9%
13 Gen 2 29 74 16 7 kg/43.8% 8 kg/50%
14 Gen 2 39 117 47 14 kg/29.8% 20 kg/42.6% 22 kg/47% 15 kg/32%
15 Gen 2 44 135 67 13 kg/19.4% 20 kg/29.9% 29.5 kg/43.8% 30 kg/45%
16 Gen 2 51 133 74 10 kg/13.5% 9 kg/12.2% 5.5 kg/8.2% Lost to f/u
17 Gen 2 46 141 73 13 kg/17.8% 22 kg/30.1% 22 kg/30.1% 20 kg/27.4%
18 Gen 2 37 98 32 6 kg/18.8% 8 kg/25% 10 kg/31% 8 kg/25%
Mean 11.1 kg/26% 15.7 kg/36% 20.4 kg/40% 24.4 kg/48.8%
1502 OBES SURG (2011) 21:1499–1507not healed in spite of Pantoprazole 40 mg BID, and
Helicobacter pylori infection was documented. Follow-up
endoscopy 2 months later, after treatment for H. pylori
infection, revealed complete healing of the gastritis.
Patient no. 3 had an adjustment for diminished weight
loss. The inflation was performed without re-introducing
the endoscope to observe for inflation tube kinking. The
tube was kinked and burst, requiring balloon extraction.
The patient tolerated the procedure without clinical event.
Patient no. 6 reported to the principal investigator a
sensation of balloon deflation for 1 month. Endoscopy
revealed a completely deflated balloon with the anchor in
the stomach. The balloon was removed without clinical event.
Patient no. 13 had a Mallory–Weiss tear several days
after an adjustment. The device was removed, and the
patient was sent home the same day. The patient’s
hemoglobin was stable, and no additional clinical events
were noted.
Patient no. 10 had a leak after her valve broke during her
third adjustment procedure. The valve remained intact,
connected to the balloon, but allowed a slow leak. The device
was removed, and the patient was sent home the same day.
The valve has two parts which were glued together. The two
parts of the valve are now secured using heat welding.
Patient no. 9 took 2 weeks of Piroxicam 20 mg daily
plus three to four doses of Ibuprofen daily every day for
low back pain. She then presented with a gastric perfora-
tion. At laparotomy, a NSAID-induced perforating gastric
ulcer was oversewn. The device was noted to be intact, and
the perforation was deemed to be a SAE from NSAID
overdose. The patient was discharged and did well
postoperatively.
The first three cases took 20–60 min to implant due to a
floppy guidewire. After substituting a stiffer guidewire, the
remaining implantations took 8 to 15 min. Three patients
with Generation 1 device (without the stabilizer band) had
migration of the distal catheter into the duodenum. None
with Generation 2 device had distal catheter migration. One
patient with Generation 2 device (with stabilizer band) had
passage of the small loop of the catheter into the
duodenum. All four patients had the catheter pulled back
to its normal position in the stomach and did not have a
recurrence over the ensuing 20 or more weeks.
Table 3 Adjustments
Patient
no.
BMI Weight
(kg)
Week of
adjustment
Amount adjusted (+/
−)m l
Weight lost prior to adjustment
(kg/week)
Additional weight lost after adjustment
(kg/week)
1 39 135 26 +200 13 kg/26 weeks 7.5 kg/26 weeks
2 42 115 18 +125 23 kg/18 weeks 22 kg/34 weeks
4 36 123 20 +150 25.5 kg/20 weeks 10 kg/13 weeks
43 2 −150 35.5 kg/33 weeks 5.5 kg/19 weeks
9 32 98 10 +200 4 kg/10 weeks 5 kg/14 weeks
10 33 89 4 −50 6.5 kg/4 weeks 0.5 kg/4 weeks
10 9 +150 7 kg/8 weeks 7.5 kg/16 weeks
11 41 110 2 −50 8 kg/2 weeks 21 kg/50 weeks
12 33 98 13 +150 4.5 kg/13 weeks 3.5 kg/11 weeks
12 −150 8 kg/24 weeks +5 kg/28 weeks
14 39 117 1 −100 6.8 kg/1 week 8.2 kg/51 weeks
15 44 135 12 +200 13 kg/12 weeks 17 kg/40 weeks
16 51 133 24 +300 8.5 kg/24 weeks +3 kg/12 weeks
18 37 98 14 +200 6 kg/14 weeks 2 kg/38 weeks
17 45 141 24 −100 21 kg/24 weeks +1 kg/28 weeks
13 29 74 24 +200 8 kg/24 weeks Mallory–Weiss tear 3 days later. Balloon
removed
Upward adjustment yielded an additional 7 kg weight loss post-adjustment
Downward adjustment alleviated intolerance and yielded additional 4.6 kg weight loss post-adjustment
Adjustment procedure times ranged from 4–10 min and averaged 8 min. All were done under conscious sedation.
Table 2 Compliance
Patients Compliance Patients
with >25%
EWL
2, 3, 4, 5, 6, 7, 8, 10, 11, 13,
14, 15, 18
Excellent (7); Very
good (6)
10/13
1, 9, 12, 16, 17 Fair (2); Poor (3) 2/5
Excellent = attended all visits; Very good = attended >50% of visits;
Fair = attended <50% of visits; Poor = attended <25% of visits
OBES SURG (2011) 21:1499–1507 1503Patient no. 3 passed a sheared catheter in her bowel
movementuneventfully.Thechainendcutthroughthewallof
the catheter and caused a shearing of the catheter. The balloon
remainedintactinherstomachandwassubsequentlyremoved
uneventfully. The patient experienced upper abdominal
discomfortintermittently over a 2-day period, prior to passage
of the catheter. During the extraction procedure of patient no.
11, a deep laceration was noted in the proximal esophagus.
The chain-end had sheared through the wall of the catheter
(similar to patient no. 3) and scratched the esophagus during
extraction. Barium swallow did not show an extravasation or
perforation, but the surgeon elected to repair it surgically
through a neck incision. She was discharged from the hospital
1 week later, without dysphagia.
Balloons were extracted by ensnaring the blue clasp with
a polypectomy snare. During the course of this study, CE
Mark was granted based on pre-clinical studies, literature
review, technical file review, and preliminary results of this
study. All engineering enhancements have been docu-
mented, verified, and validated according to the medical
directive. As a result of the adverse events, several changes
were made. (1) The IFU will stipulate “any erosive
gastritis” as a contraindication. (2) A stretchable stabilizer
band that spans the diameter of the large loop of the
catheter was added. This keeps the catheter loop closed in
the deployed position and resists opening of the loop, with
the exception of insertion and extraction. (3) The metal
chain will be curved and will have atraumatic ends
surrounded by silicone glue to prevent catheter shearing.
The addition of the stabilizer band also prevents catheter
shear by preventing repetitive opening and closing of the
loop. The catheter wall has now been reinforced with a strain
relief band, as well. The catheter shear occurred on the radio-
opaque stripe on the catheter wall—its weakest point. The
“stripe” will be eliminated since the metal chain makes the
“stripe” superfluous. (4) To address the small loop migration
into the duodenum, a second chain and stabilizer band were
added to the smaller loop in a post-market release. This
addition caused difficulty in guidewire release during inser-
tion. Since the migration of the small loop occurred in only
one of 18 patients in our study (without recurrence) and
caused minor nausea and vomiting, the second chain and
stabilizer band have thus been removed.
Discussion
Currently marketed IGBs, in their varying embodiments, are a
static technology. The choice of balloon volume is made at the
time of implantation—and is not easily changed. There is no
way to gauge what size balloon is best for a specific patient, as
the threshold for nausea vomiting and/or abdominal pain are
not measurable or predictable. The loss of IGB efficacy after
3monthshasbeen demonstratedconvincingly inmany studies
[3, 16, 18–22] and is considered a major drawback. This has
led researchers to evaluate placement of a second balloon
1 month after removal of the first balloon. In a recent study,
Lopez-Nava reported an additional drop of 2.6 points of BMI,
following consecutive balloon placements in 112 patients
[23]. In a similar study of consecutive BIB balloons, Genco
reported a further drop of 3.9 points of BMI after the second
balloon [24]. This upward adjustment was enacted using two
consecutive “static” balloons—requiring two balloons and
four endoscopic procedures. An adjustable balloon, on the
other hand, offers dynamic bariatric therapy—requiring one
balloon and three endoscopic procedures. Our study has
shown the safety and efficacy of an adjustable balloon.
Weight loss plateaus were treated with volume additions.
Intolerance was successfully managed with a downward
adjustment—patients regained their comfort, yet continued to
lose weight. Both the downward and upward adjustments
resulted in significant (4.6 and 8.1 kg, respectively) weight
loss following the adjustment.
IGBs carry a risk of migration of the deflated balloon
and bowel obstruction. The largest BIB series reported 19
incidents of early gastric/duodenal obstruction. Eight
occurred in partially deflated balloons which entered and
Table 5 Post-implantation symptoms:
Patients Severity Patients with >25% EWL
1, 3, 5, 7, 13, 18, Mild 4/6
2, 8, 9, 10, 12, 17 Moderate 3/6
4, 6, 11, 14, 15, 16 Severe 5/6
Mild = <2 days vomiting, and <3 vomits per day; Moderate = 2–
5 days of vomiting or vomit up to 5× a day; Severe = >6 vomits/day
or > 5 days of vomiting
Patient no. Comorbidity Weight loss/Time Comment
5 Diabetes 16 kg/6 months DM stable
Hypertension BP Controlled
17 Diabetes 21.5 kg/6 months HbA1c from 5.9 to 4.2
3 Hypertension 24 kg/6 months BP to 100/60 Meds stopped
13 Hypertension 8 kg/6 months BP controlled
Table 4 Comorbidities
1504 OBES SURG (2011) 21:1499–1507blocked the pylorus. The other 11 obstructions occurred
with normally inflated balloons and could not be explained
by the authors [25]. We have encountered only one episode
of spontaneous balloon deflation in one of our early
implantations. The one episode of balloon deflation was
rectified by additional adhesive between the catheter and
the balloon edge. Our incidents of duodenal migration of
our distal catheter tip in our first generation device have
prompted the addition of the stabilizer band, which appears
to have successfully prevented distal catheter tip migration.
The addition of a stretchable stabilizer band that “closes the
loop” of the “anchor” and exerts a force against the
straightening of the “anchor” seems to prevent entrance
into the duodenum. The combination of the internal chain
(prevents collapse of the loop) and the stabilizer band
(prevents opening of the loop) maintain the “anchor” in a
7-cm diameter circle that hampers device migration in the
event of balloon deflation—yet allows straightening for
insertion and extraction.
Two critical reviews of IGBs have been reported in the
literature, with similar overall positive results [1, 2]. IGBs
are an established successful weight loss therapy with 5,000
patients reported in the literature over the last 17 years [3–
16]. Only a handful of studies report negative or equivocal
results [26–28].Two randomized controlled trials (RCT)
with crossover have been published [7, 29]. The Mathus-
Vliegen study found no difference in weight loss between
sham and BIB groups in the first 13 weeks of the study.
However, after crossover, the BIB group lost 4.9 kg more
than the sham group [29]. In contrast, the Genco RCT with
crossover study did show a 12 kg greater weight loss for the
BIB over the sham group in the first half of the study. After
crossover, again, the BIB group lost 7 kg more than the
sham group [7]. The mechanism of action for weight loss
with the IGB may be multifactorial. Aside from the obvious
space occupying effect of IGBs, Ghrelin levels (an appetite
enhancing hormone discovered in the stomach) have been
documented to decrease during balloon implantation in one
study [4] and uncorrelated in another study [26]. Prolonged
gastric emptying has also been demonstrated during IGB
implantation [4].
Over 100,000 IGBs have been implanted worldwide,
with an impressive safety record and reproducible efficacy.
Nonetheless, there remain issues and risks with current IGB
technology.
Early nausea has been reported in every published BIB
study. In one review, early balloon removal was reported in
143 out of 3,442 patients (4.2%) in 13 of the articles
reviewed [2]. In another review, early balloon removal was
noted in 6.7%, but if the 2,515 patients in the Genco study
were added then these numbers are halved [1]. Given the
lack of volume adjustability in current IGBs, endoscopists
Patient
no.
Event Week
no.
Relation to device/
procedure
Comment
7 Pregnancy 8 Unrelated Removed during second trimester
5 Erosive
gastritis
a
6 Device related Patient implanted with mod-severe erosive
gastritis that did not heal
with PPI
3 Inflation tube
leak
a
8 Procedural error First adjustment performed without
endoscopic observation
6 Balloon leak
a 18 Device related
malfunction
Early generation device had insufficient
glue between balloon and catheter
13 Mallory–
Weiss tear
a
24 Procedure related Vomiting after adjustment
10 Valve broke
a 28 Device related Two parts of the valve bonded by glue
(newer model uses improved
heat bonding)
9 Gastric
perforation
a
28 Unrelated Patient took double dose NSAIDS
(piroxicam and ibuprofen) × 14 days
for low back pain
Table 7 Device removals
aDiscussions about each patient
are explained in the text
Symptom No. of episodes/day Duration Severity % of patients w/symptom
Nausea 1–2 days Mild 20%
Vomiting 1–2 per day 1–2 days Mild 50%
Abdominal pain 0 0 0 0%
Table 6 Post-adjustment
symptoms
OBES SURG (2011) 21:1499–1507 1505aim for the highest tolerated balloon volume, at the risk of
greater nausea and vomiting and early balloon removal.
The correct volume is an unknown for each patient. An
adjustable balloon, however, can start with a smaller
volume balloon with the expectation of increasing volume
after two to 3 months (or when weight loss diminishes),
offering a more comfortable early period. Although we only
report our first 18 patients, their early period has been
comfortable, with two of our patients (patient nos. 11 and
14) requesting downward adjustment to combat intolerance.
They remained in the study and continued to lose weight.
Only an adjustable balloon can offer this advantage.
The 2008 Mathus-Vliegen review reported a 3.3–8%
balloon deflation rate within 6 months. She found that 25%
of the deflated balloons remained in the gastric lumen; 71%
passed harmlessly in the stool and 4% required surgery to
alleviate bowel obstruction [1]. It is widely accepted and
intuitively reasonable to assume that deflation rates increase
with longer acid exposure. Intestinal obstruction has been
reported with deflated balloons [5, 6, 9, 25, 30–32], and as
such IGB removal at 6 months is mandated. The Spatz
balloon “anchor” enhances endoscopic retrieval of a
deflated balloon and will diminish the risk of bowel
obstruction. This in turn has allowed a longer 6-month
implantation, granted by the CE Mark. Only one of our
patients had a balloon leak. The patient reported this to us
1 month after sensing the deflation. Upon balloon retrieval,
the anchor was noted sitting in the gastric antrum with the
deflated balloon attached. Although it is only one episode,
it does confirm the anchor function. Whereas our early
generation device had distal catheter entry into the pylorus
in three of five patients, it did not occur in the 13 patients
that had a stabilizer band added in the Generation 2 device.
If a Spatz balloon does deflate, and even if there is catheter
entry into the pylorus, migration of the device and deflated
balloon would be significantly hampered by the catheter,
internal chain, and stabilizer band—allowing time for
endoscopic retrieval. Deflation of the Allergan intragastric
balloons have reported a 4% chance of bowel obstruction
[1]—it cannot be studied, but it has been suggested that
deflated balloons leave the stomach within hours and leave a
very short window of opportunity for endoscopic retrieval.
There is no safeguard for preventing migration—other than
methylene blue causing a change in urine color. The Spatz
balloon is the first intragastric balloon to attempt a
mechanical means to prevent balloon migration.
Weight loss maintenance after balloon extraction has been
reportedwithmixed results [6, 12, 27, 28, 33]. One year after
IGB removal, patients regained 75% [27], 41% [12], and
28% [28] of their lost weight. Crea reported a regain of three
points of BMI 1 year after IGB removal; however, the
maintenance of at least 10% of the body weight loss % was
associated with an improvement in metabolic syndrome.
Negrin Dastis reported the maintenance of at least 10%
weight loss in 24% of patients at 2.5 years post-balloon
explantation [29].
IGB programs stress continued follow-up for behavior
modification which has limited success in the post-
extraction period. Longer implantation times afford longer
behavior modification times, which can presumably reap
better weight loss maintenance results.
The overall function and safety of the device has been
demonstrated in this pilot, first-in-man study. Although one
balloon leaked and one valve malfunctioned (after third
adjustment), these issues have been addressed with engi-
neering enhancements. The presence of erosive gastritis has
been shown to be a contraindication, as has been the use of
NSAIDs. Our subject who double-dosed NSAIDs (Pirox-
icam and Ibuprofen) for 2 weeks developed a perforating
NSAID ulcer—determined by the principal investigator to
be unrelated to the device. One case of Mallory–Weiss tear
after multiple bouts of vomiting is not unusual in this
clinical setting. The episodes of catheter shear have been
successfully addressed by engineering enhancements and
will be reported in a forthcoming publication.
The Future
The introduction of an adjustable IGB with an attached
“anchor” can potentially bring endoscopic “temporary”
bariatric therapy to the level of endoscopic chronic weight
management.
Our study is the first step towards changing the path of
IGB therapy. The options are numerous. Sequential volume
additions at every weight loss plateau, interspersed with
6 week “holidays” with a partially deflated balloon (to
achieve a renewed effect), are now within our grasp. Trial
of balloon deflation prior to extraction can identify potential
relapsers (weight regain). The elimination of the obstruction
risk by the “anchor” has allowed regulatory approval of
12 month implantation times. Longer implantation times
afford greater weight loss, more effective behavior modifi-
cation, and improved weight loss maintenance. Further
studies will begin to tackle these questions. In the
meantime, the technology has arrived.
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